Clinical Implications of Expression of Interleukin 8 Related to Angiogenesis in Uterine Cervical Cancers

Jiro Fujimoto,1 Hideki Sakaguchi, Ikumi Aoki, and Teruhiko Tamaya

Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu City 500-8705, Japan

ABSTRACT

There was a significant correlation between microvessel counts and interleukin (IL-8) levels and between microvessel macrophage counts and IL-8 levels in uterine cervical cancers. Immunohistochemical staining revealed that the localization of IL-8 was similar to that of CD68 for macrophages. The prognosis of the 20 patients with high IL-8 (>1000 pg/mg protein) in uterine cervical cancers was extremely poor, whereas the 24-month survival rate of the other 60 patients with low IL-8 (<1000 pg/mg protein) was 67%. Therefore, this indicates that IL-8 might be a prognostic indicator as an angiogenic factor supplied from macrophages within and around the tumor.

INTRODUCTION

Angiogenesis is essential for development, growth, and advancement of solid tumors (1). Although angiogenic factors for tumor angiogenesis have been considered to be produced by tumor cells, it has been demonstrated that they are also produced by interstitial cells within and around the tumor. In uterine cervical cancers, especially adenocarcinomas of the cervix, VEGF (9) (particularly the VEGF 165 and VEGF 121 isoforms) was dominantly expressed in cancer cells (2). Furthermore, VEGF levels correlated with microvessel density (2). However, bFGF and PD-ECGF were expressed in both cancer and interstitial cells of uterine cervical cancers, and PD-ECGF was dominantly expressed in interstitial cells of squamous cell carcinomas of the cervix (3, 4). Furthermore, PD-ECGF levels correlated with microvessel density and patient prognosis in metastatic and primary lesions of uterine cervical cancers (4, 5).

It is well known that infiltration of inflammatory cells is activated in malignant tumors, which contributes to angiogenesis. The tumor-associated macrophage has been recognized as a candidate among inflammatory cells for tumor angiogenesis (6). The macrophages that infiltrate tumors of the liver and the gastrointestinal tract supply bFGF (7), and those that infiltrate breast and ovarian cancers supply VEGF (8) and TNF-α (9). Although TNF-α possesses weak angiogenic activity in itself, the angiogenic potential of TNF-α appears to be modulated through induction of the strong angiogenic factors IL-8, VEGF, and bFGF, and this pathway is regulated through paracrine and/or autocrine mechanisms (10). IL-8 is expressed in macrophages and fibroblasts derived from the interstitium (7) and was recognized as a macrophage-derived mediator of angiogenesis (11). This prompted us to study the clinical implications of macrophage-derived angiogenesis in uterine cervical cancers.

MATERIALS AND METHODS

Patients. Consent for the following studies was obtained from all patients and from the Research Committee for Human Subjects, Gifu University School of Medicine. Eighty patients ranging from 37–74 years of age underwent curative resection for cervical cancer. Patient prognosis was analyzed with a 24-month survival rate after curative resection at the Department of Obstetrics and Gynecology, Gifu University School of Medicine between June 1994 and April 1997. None of the patients had received any preoperative therapy. A part of each uterine cervical cancer tissue was obtained immediately after hysterectomy and snap-frozen in liquid nitrogen to determine the levels of IL-1α, IL-1β, TNF-α, IL-8, bFGF, VEGF, and PD-ECGF, and a neighboring part of the tissue was submitted for histopathological study. The clinical stage of uterine cervical cancers was determined by the FIGO classification (12).

Immunohistochemistry. Four-μm sections of formalin-fixed paraffin-embedded tissue of uterine cervical cancers were cut with a microtome and dried overnight at 37°C on a silanized slide (DAKO, Carpinteria, CA). Samples were deparaffinized in xylene at room temperature for 80 min, washed with a graded ethanol/water mixture, and then with distilled water. The samples for IL-8 and CD68 antigens were soaked in a citrate buffer and then microwaved at 100°C for 10 min, and those for factor VIII-related antigen were treated with 0.3 µg/ml trypsin in PBS at room temperature for 20 min. The protocol for DAKO LSAB2 Kit Peroxidase (DAKO) was followed for each sample. In the described procedures, rabbit antihuman IL-8 (Biosource, CA), mouse antihuman macrophage CD68 (DAKO), and rabbit anti-factor VIII-related antigen (Zymed, San Francisco, CA) were used at dilutions of 1:50, 1:50, and 1:2, respectively, as the first antibodies. The addition of the first antibody, rabbit antihuman IL-8, mouse antihuman macrophage CD68, or rabbit anti-factor VIII-related antigen, was omitted in the protocols for negative controls of IL-8, CD68, or factor VIII-related antigen, respectively.

Enzyme Immunoassay for Determination of IL-1α, IL-1β, TNF-α, IL-8, bFGF, VEGF, and PD-ECGF Antigens. All steps were carried out at 4°C. Tissues of uterine cervical cancers (wet weight, 10–20 mg) were homogenized in HG buffer [5 mM Tris-HCl (pH 7.4), 5 mM NaCl, 1 mM CaCl2, 2 mM ethyleneglycol-bis-[β-aminoethylether]-N,N,N’,N’-tetraacetic acid, 1 mM MgCl2, 2 mM DTT, 25 µg/ml aprotinin, and 25 µg/ml leupeptin] with a Polytron homogenizer (Kinematics, Luzern, Switzerland). This suspension was centrifuged in a microfuge at 12,000 rpm for 3 min to obtain the supernatant. The protein concentration of samples was measured by the method of Bradford (15) to standardize IL-1α, IL-1β, TNF-α, IL-8, bFGF, VEGF, and PD-ECGF antigen levels.

IL-1α, IL-1β, TNF-α, IL-8, bFGF, and VEGF antigen levels in the samples were determined by a sandwich enzyme immunoassay using human IL-1α quantitine (R&D Systems, Minneapolis, MN), human IL-1β quantitine (R&D Systems), human TNF-α quantitine (R&D Systems), human IL-8 quantitine (R&D Systems), human bFGF quantitine (R&D Systems), and human VEGF assay kit-IBL (Immuno Biological Laboratories, Gunma, Japan), respectively, and PD-ECGF antigen levels were determined by the method described by Nishida et al. (16). The levels of IL-1α, IL-1β, TNF-α, IL-8, bFGF, VEGF, and PD-ECGF were standardized with the corresponding cellular protein concentrations.

Statistics. Survival curves were calculated using the Kaplan-Meier method and analyzed by the log-rank test. IL-1α, IL-1β, TNF-α, IL-8, bFGF, VEGF, and PD-ECGF levels were measured from three parts of the same tissue in
triplicate. Statistical analysis was performed with Student’s $t$ test. Differences were considered significant when $P$ was less than 0.05.

RESULTS

There was a significant correlation between MVCs and IL-8 ($P < 0.01$, as shown in Fig. 1), bFGF ($P < 0.01$), VEGF ($P < 0.01$), and PD-ECGF levels ($P < 0.01$) in uterine cervical cancers, but not between MVCs and IL-1α, IL-1β, or TNF-α.

There was a significant correlation between IMCs and IL-8 levels in uterine cervical cancers, as shown in Fig. 2 ($P < 0.01$), but not between IMCs and IL-1α, IL-1β, TNF-α, bFGF, VEGF, or PD-ECGF (data not shown).

Immunohistochemical staining for IL-8 and CD68 in a representative case of adenocarcinoma is shown in Fig. 3. IL-8 was distributed in the interstitium within and around the tumor. CD68 was found in a localization and manner similar to IL-8 in all cases.

There was no significant correlation between histopathological type...
and IL-8 levels, as shown in Fig. 4. There was a significant difference
\((P < 0.05)\) in IL-8 levels between early-stage (stage I) and late-stage
(stages II–IV) uterine cervical cancers, as shown in Fig. 5.

The prognosis of the 20 patients with high IL-8 (>1000 pg/mg
protein) in uterine cervical cancers was extremely poor, whereas the
24-month survival rate of the other 60 patients with low IL-8 (<1000
pg/mg protein) was 67% (Fig. 6).

**DISCUSSION**

Infiltrated macrophages in tumors are activated, which leads to the
induction of angiogenic potential; in fact, macrophage infiltration
correlates with microvessel density in breast cancers (6). In the
present study, there was a significant correlation between IMC and
MVC \((P < 0.05)\) in uterine cervical cancers (data not shown).
Therefore, we studied which angiogenic factors derived from tumor-
associated macrophages promote tumor angiogenesis in uterine cer-
vical cancers. Generally, bFGF, VEGF, PD-ECGF, TNF-\(\alpha\), and IL-8
have been recognized as tumor-associated macrophage-derived angio-
genic factors (7–11).

In the present study, the positive correlation between MVCs and
IL-8, bFGF, VEGF, and PD-ECGF demonstrates that these factors
work as angiogenic factors. In uterine cervical cancers, VEGF from
cancer cells is related to patient prognosis, but only in early invasion
(2, 17, 18). PD-ECGF from the interstitial cells correlates with patient
prognosis, especially with lymph node metastasis (4, 5). bFGF from
both the cancer and interstitial cells relates to clinical stage and
advancement (3). Although PD-ECGF and bFGF were provided in
part from tumor-associated macrophages, macrophage infiltration was
positively correlated with only IL-8 among IL-1\(\alpha\), IL-1\(\beta\), TNF-\(\alpha\),
bFGF, VEGF, PD-ECGF, and IL-8, which demonstrates that IL-8
might be dominantly supplied from tumor-associated macrophages.
Furthermore, localization of IL-8 in the tumors was similar to that of
macrophage CD68. Although there is no distinct cytokine network
among IL-1\(\alpha\), IL-1\(\beta\), TNF-\(\alpha\), and IL-8 in tumor angiogenesis derived
from infiltrated macrophages, it is strongly speculated that IL-8 works
as an angiogenic factor in uterine cervical cancers. In other
angiogenesis-dependent diseases, IL-8 contributes to growth related to
angiogenesis in bronchogenic carcinoma (19), glioblastoma (20),
melanoma (21), ovarian carcinoma (22, 23), and other cancers. Fur-
thermore, IL-8 activates metastatic potential (21).

In the present study, IL-8 levels were significantly increased during
the advancement from stage I to stages II, III, and IV. Therefore, IL-8
might be the angiogenic switch in advancement to later stages of
uterine cervical cancers. Furthermore, IL-8, as an angiogenic factor
supplied from infiltrated macrophages within and around the tumor,
might be a prognostic indicator.

**REFERENCES**

2. Fujimoto, J., Sakaguchi, H., Hirose, R., Ichigo, S., and Tamaya, T. Expression of
vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.


Clinical Implications of Expression of Interleukin 8 Related to Angiogenesis in Uterine Cervical Cancers

Jiro Fujimoto, Hideki Sakaguchi, Ikumi Aoki, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/10/2632

Cited articles
This article cites 21 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/10/2632.full.html#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
content/60/10/2632.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.